(A) Percentage of uTregs (Foxp3+ cells within CD4+CD25-) in the lung tissues of abatacept IN, abatacept IP treated, or OVA challenged mice. (B) Percentage of LAG3+ uTregs (CD25-Foxp3+LAG3+) in the lung tissues of abatacept IN, abatacept IP treated, or OVA challenged mice. (C) Percentage of uTregs in the PBMCs of abatacept IN, abatacept IP treated, or OVA challenged mice. (D) Percentage of LAG3+ uTregs in the lung tissues of abatacept IN, abatacept IP treated, or OVA challenged mice. Lung tissues of 5 mice and PBMCs of 10 mice were used. Two-way unpaired t-test was used to calculate significance. ****P < 0.001. Events were recorded and analysed by using BD FACSDiva version 8.0.